Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06077838 · ClinicalTrials.gov registry record · NA

RELAXaHEAD for Headache Patients (Phase III)

A NA study of Migraine, sponsored by NYU Langone Health.

Recruiting
Registry status
NA
Development phase
356
Enrollment target
1
Study location

NCT06077838 is a NA study of Migraine that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 356 participants, roughly in line with the 355-participant average among 102 other Migraine trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06077838, a NA study of Migraine, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
NA
Development phase
356 participants
Enrollment target
1
Study location

Study Summary

This study is a fully powered, remote randomized control trial to evaluate RELAXaHEAD in people with migraine.

Conditions Studied

Interventions

  • BEHAVIORAL RELAXaHEAD Smartphone App Version 1
  • BEHAVIORAL RELAXaHEAD Smartphone App Version 2

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 356 participants
Start Date 2023-11-08
Est. Completion 2028-08-31
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT06077838

The ClinicalTrials.gov registry entry for NCT06077838 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 355-participant average among 102 other Migraine trials with a reported enrollment target. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which RELAXaHEAD Smartphone App Version 1 is the first listed.

NCT06077838 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06077838 about?

NCT06077838 is a clinical study titled "RELAXaHEAD for Headache Patients (Phase III)". This study is a fully powered, remote randomized control trial to evaluate RELAXaHEAD in people with migraine.

What is the current status of trial NCT06077838?

This trial is currently recruiting. It is a NA study. The enrollment target is 356 participants. The study started on 2023-11-08. Estimated completion is 2028-08-31.

What conditions does trial NCT06077838 study?

This clinical trial studies the following conditions: Migraine.

What interventions are being tested in trial NCT06077838?

The interventions under investigation include: RELAXaHEAD Smartphone App Version 1 (BEHAVIORAL), RELAXaHEAD Smartphone App Version 2 (BEHAVIORAL).

Who is sponsoring clinical trial NCT06077838?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06077838 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.